查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018642

智慧切片检查设备市场：2026-2032年全球市场预测（按产品类型、引导技术、组件、应用和最终用户划分）

Smart Biopsy Devices Market by Product Type, Guidance Technology, Component, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，智慧切片检查设备市场价值将达到 58.5 亿美元，到 2026 年将成长至 62.2 亿美元，到 2032 年将达到 91.1 亿美元，复合年增长率为 6.53%。

主要市场统计数据
基准年 2025 58.5亿美元
预计年份：2026年 62.2亿美元
预测年份 2032 91.1亿美元
复合年增长率 (%) 6.53%

本文简要说明了诊断影像技术的创新、手术效率的提高以及临床需求的融合如何重塑现代切片检查设备策略。

智慧切片检查设备的演进是临床需求与技术能力融合的结果，需要精心的策略规划。影像技术、针头设计和引导软体的进步，在提高诊断准确性的同时，也正在重塑所有医疗机构的流程。随着临床医生对微创技术的需求日益增长，这些技术既能提高组织取样的准确性，又能降低患者的风险，设备开发人员和医疗系统正积极响应，整合自动化平台，简化规划、导航和文件记录流程，提供即时影像引导，并建立可互通的软体堆迭。

技术、临床工作流程和商业方面的重大变革正在重塑切片检查设备的竞争定位和推广路径。

过去几年，临床实务和产品研发领域发生了翻天覆地的变化，智慧切片检查设备的竞争格局也因此发生了根本性的改变。首先，影像引导的精准性已从辅助功能转变为核心功能需求，推动了硬体、软体和资料分析的深度整合。因此，製造商优先开发模组化平台，这些平台能够接收多种影像输入，并透过回馈迴路实现确定性的针头定位，从而减少操作者差异。

2025 年关税变化将对医疗设备製造和临床导入过程中的供应链、采购方式和产品策略带来压力。

2025年公布的关税措施的累积影响对智慧切片检查设备整个价值链的供应链结构和成本结构产生了切实的营运和策略影响。影响医疗设备零件和精密合金的关税措施迫使製造商重新评估其供应商组合，加快供应商在免税地区的认证，并考虑本地组装以降低不断上涨的接收成本。在许多情况下，由于企业需要对冲供应中断和财务不确定性，这些调整导致专案管理负担加重和库存增加。

基于详细细分的分析揭示了产品、应用、指导技术、最终用户和组件的差异如何影响临床和商业性路径。

细分市场分析提供了一种系统性的观点，用于识别临床需求、技术能力和商业性机会的交集。根据产品类型，市场参与企业将其产品分为「自动化平台」和「手动平台」。自动化带来工作流程的一致性，而手动设备则为许多操作者提供熟悉的操作体验。这种二元性会影响产品设计和培训投入，因为自动化解决方案需要软硬体的紧密整合，而手动平台则更注重人体工学和触觉回馈。

区域趋势和策略挑战：这重点介绍了临床重点、法规和基础设施如何影响全球市场的设备部署。

区域趋势揭示了独特的临床重点、法规环境和采购行为，这些因素会影响部署模式和伙伴关係策略。在美洲，医疗服务体系的特点是高度专业化、拥有先进的影像基础设施，并高度重视微创诊断途径。这些因素有利于那些展现出高效操作、报销相容性以及与现有影像平台互通性的医疗设备。此外，支付方的成本意识和医院的预算週期通常也会影响采购时机以及高成本整合解决方案的采用。

透过临床证据、综合服务和可扩展的商业化模式，打造竞争格局和伙伴关係关係，从而脱颖而出。

智慧切片检查领域的竞争动态由众多参与者共同塑造，其中包括成熟的医疗设备製造商、影像系统供应商、专注于特定Start-Ups需求的敏捷型新创公司，以及提供导航和分析功能的软体公司。这些参与者透过提供临床证据、系统整合、售后服务和策略伙伴关係关係来脱颖而出。能够展现明确疗效优势的公司，例如降低併发症发生率、提高诊断准确率或提升工作流程效率，往往能够与医疗机构建立更牢固的合作关係，并获得更优厚的合约待遇。

为製造商和医疗保健领导者提供切实可行的多方面建议，以确保供应链的韧性、临床有效性和永续的商业性差异化。

产业领导者应采取多管齐下的策略，兼顾短期业务永续营运和长期平台差异化。首先，为降低贸易政策波动风险并缩短关键零件的前置作业时间，他们应在经济可行的范围内优先考虑供应链多元化和近岸外包。此外，还必须辅以严格的供应商筛选流程和情境规划，以确保针头和诊断影像配件等大量耗材的持续供应。

我们严谨的混合方法研究框架，结合了对临床医生的访谈、供应链分析、监管审查和专家检验，确保了可靠且可操作的见解。

本研究途径融合了定性和定量方法，旨在全面检验市场动态、临床应用驱动因素和竞争优势。初步研究包括对放射科、介入性肿瘤科和泌尿系统等不同专科的临床医生以及医院、门诊手术中心和诊断中心的采购经理进行结构化访谈，以收集关于医疗设备需求、工作流程限制和采购标准的第一手观点。除访谈外，还与医疗设备工程师、监管专家和零件供应商进行了讨论，以明确研发进度和采购考量。

对决定哪种切片检查设备策略能够带来持续的临床应用和商业性成功的临床、技术和策略因素进行简洁的整合。

总而言之，智慧切片检查设备的演进反映了向整合式手术解决方案的广泛转变，这种解决方案融合了精准引导、优化的工作流程和软体驱动的价值创造。临床上对微创和高精度取样的需求，以及影像和导航技术的进步，为能够满足不同应用和临床环境需求的差异化平台创造了机会。同时，关税变化和区域监管差异等外部压力迫使製造商重组其供应链和经营模式，以维持获利能力并确保向临床机构不间断供应。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：智慧切片检查设备市场：依产品类型划分

  • 自动的
  • 手动的

第九章 智慧切片检查设备市场指南（依技术分类）

  • CT引导
  • 磁共振引导
  • 超音波引导

第十章：智慧切片检查设备市场：按组件划分

  • 配件
  • 导航软体
  • 影像系统
  • 针
    • 厚直径
    • 中型轨距
    • 细直径

第十一章 智慧切片检查设备市场：按应用领域划分

  • 胸部
  • 肝
  • 肺
  • 摄护腺

第十二章 智慧切片检查设备市场：依最终用户划分

  • 门诊手术中心
  • 诊所
  • 诊断中心
  • 医院

第十三章：智慧切片检查设备市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 智慧切片检查设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 智慧切片检查设备市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国智慧切片检查设备市场

第十七章：中国智慧切片检查设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Angiotech Pharmaceuticals, Inc.
  • Argon Medical Devices, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • CONMED Corporation
  • Cook Group Incorporated
  • Danaher Corporation
  • DTR Medical Ltd. by Innovia Medical
  • Fujifilm Holdings Corporation
  • Gallini Srl
  • Hologic, Inc.
  • INRAD, Inc.
  • Intact Medical Corporation
  • Integra LifeSciences Corporation
  • Leica Biosystems Nussloch GmbH
  • Medtronic PLC
  • Merit Medical Systems
  • Olympus Corporation
  • Precision Biopsy, LLC
  • Scion Medical Technologies, LLC
  • Stryker Corporation
  • TransMed7, LLC
  • TSK Laboratory Europe BV
Product Code: MRR-221461476EF5

The Smart Biopsy Devices Market was valued at USD 5.85 billion in 2025 and is projected to grow to USD 6.22 billion in 2026, with a CAGR of 6.53%, reaching USD 9.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.85 billion
Estimated Year [2026] USD 6.22 billion
Forecast Year [2032] USD 9.11 billion
CAGR (%) 6.53%

A concise orientation to the convergence of imaging innovation, procedural efficiency, and clinical demand reshaping modern biopsy device strategies

The smart biopsy device landscape is converging clinical necessity and technological capability in ways that demand close strategic attention. Advances in imaging modalities, needle design, and guidance software are increasing diagnostic precision while reshaping procedural workflows across care settings. As clinicians push for minimally invasive techniques with improved tissue acquisition and reduced patient risk, device developers and health systems are adapting through integration of automated platforms, real-time imaging guidance, and interoperable software stacks that streamline planning, navigation, and documentation.

Against this backdrop, regulatory scrutiny and reimbursement pathways continue to influence product development timelines and adoption curves, while supply chain resilience and component sourcing have become quasi-strategic imperatives. Stakeholders from manufacturers to hospital procurement teams must therefore balance clinical performance with manufacturability, cost, and post-market support. In addition, the cross-pollination of innovations from adjacent imaging and surgical navigation markets is accelerating feature sets and creating new business models centered on analytics and outcomes tracking.

Taken together, these dynamics underscore the importance of a focused executive-level synthesis that highlights both the near-term operational levers and the longer-term strategic bets. The aim is to provide decision-makers with a concise yet comprehensive orientation to the forces shaping device evolution, adoption drivers across clinical settings, and the competitive responses required to maintain advantage in an increasingly sophisticated ecosystem.

Critical technological, clinical workflow, and commercial shifts that are remaking competitive positioning and adoption pathways for biopsy devices

Over the past several years, transformative shifts have accelerated in clinical practice and product development, producing a fundamentally different competitive landscape for smart biopsy devices. First, imaging-guided precision has moved from adjunctive support to a core functional requirement, driving deeper integration between hardware, software, and data analytics. As a result, manufacturers are prioritizing modular platforms that can accept multiple imaging inputs and deliver deterministic needle placement with feedback loops that reduce variability across operators.

Second, workflow optimization has become a commercial differentiator. Programs that reduce procedure time, lower complication rates, and simplify documentation attract system-level adoption. Consequently, design philosophies emphasize user-centered interfaces, automated needle deployment options, and cloud-enabled documentation that support procedural standardization. Third, convergence with digital health has introduced new monetizable services-software-as-a-service models, image analytics subscriptions, and outcome-tracking modules-that augment device revenue and deepen customer relationships.

Finally, competitive dynamics are changing as well. Smaller agile entrants are pursuing niche clinical applications and novel needle geometries, while established medtech firms leverage scale to bundle devices, imaging systems, and service contracts. Partnerships between imaging providers, software developers, and procedural device manufacturers are increasingly common, reflecting a recognition that integrated solutions win in complex clinical pathways. Altogether, these shifts demand that stakeholders rethink product roadmaps, clinical validation strategies, and go-to-market models to capture both clinical value and economic upside.

How 2025 tariff shifts have pressured supply chains, procurement behavior, and product strategies across device manufacturing and clinical adoption pathways

The cumulative impact of tariff actions announced in 2025 has introduced tangible operational and strategic consequences for supply chain configurations and cost structures across the smart biopsy device value chain. Tariff measures affecting medical device components and precision alloys have compelled manufacturers to re-evaluate supplier portfolios, accelerate supplier qualification in tariff-exempt jurisdictions, and consider localized assembly to mitigate increased landed costs. In many cases, these adjustments introduced project management overhead and inventory build-up as firms sought to hedge against supply interruptions and fiscal uncertainty.

Moreover, the tariff environment has influenced procurement behaviors among end users. Hospitals and diagnostic centers facing constrained capital budgets have heightened scrutiny on total cost of ownership, which includes not only acquisition cost but also maintenance, consumables, and the downstream operational impact of device selection. In response, vendors have emphasized transparency around component sourcing and lifecycle costs, and some have proposed alternative commercial terms-such as consumable bundling or service-inclusive agreements-to maintain competitiveness.

From a product innovation perspective, the tariff landscape has accelerated two notable responses. One, developers are exploring design simplification and material substitution where clinically acceptable, reducing reliance on high-tariff inputs. Two, companies are prioritizing differentiation through software and service layers that are less exposed to tariff fluctuations, thereby protecting margins and preserving value capture. Transitioning manufacturing footprints and diversifying supplier bases will remain an active management priority as firms seek to balance regulatory compliance, cost stability, and uninterrupted clinical supply.

Deep segmentation-driven analysis revealing how product, application, guidance technology, end-user, and component distinctions shape clinical and commercial pathways

Segmentation analysis provides a structured lens for identifying where clinical need, technological capability, and commercial opportunity intersect. Based on Product Type, market participants differentiate offerings between Automated and Manual platforms, with automation delivering workflow consistency and manual devices offering procedural familiarity for many operators. This dichotomy informs both product design and training investments, as automated solutions require tighter software-hardware integration while manual platforms prioritize ergonomics and tactile feedback.

Based on Application, clinical focus areas span Breast, Liver, Lung, and Prostate procedures, each presenting distinct anatomic and procedural constraints that shape device requirements. Breast biopsies emphasize cosmetic outcomes and outpatient procedural efficiency; liver and lung procedures demand robust imaging guidance to navigate respiratory motion and tissue heterogeneity; prostate biopsies require high spatial accuracy to align diagnostic sampling with targeted therapy planning. These application-specific imperatives drive needle design, imaging compatibility, and clinical training curricula.

Based on Guidance Technology, devices are evaluated across CT Guided, MRI Guided, and Ultrasound Guided modalities. CT guidance offers high-resolution anatomic localization in thoracic and hepatic interventions, MRI guidance excels in soft-tissue contrast and targeted prostate procedures, and ultrasound guidance provides real-time feedback and cost-effective portability. Interoperability across these guidance technologies is increasingly important as institutions seek flexible platforms that can be deployed across multiple procedure types.

Based on End User, adoption occurs across Ambulatory Surgical Centers, Clinics, Diagnostic Centers, and Hospitals, each with unique procurement cycles, staffing models, and throughput expectations. Ambulatory surgical centers and diagnostic centers often prioritize throughput and per-procedure cost efficiency, while hospitals focus on integration with broader imaging fleets and cross-departmental support. Clinics may value compact footprint and ease of use for office-based procedures.

Based on Component, device ecosystems are comprised of Accessories, Guidance Software, Imaging Systems, and Needles. Needles are further categorized across Large Gauge, Medium Gauge, and Small Gauge variants to accommodate different tissue types, sample volume needs, and clinician preferences. Component-level differentiation-such as needle lumen design, software navigation fidelity, and accessory ergonomics-drives clinician choice and impacts re-order cycles for consumables. By mapping segmentation layers to clinical workflows, stakeholders can better prioritize R&D investments and commercialization strategies that align with end-user economics and procedural outcomes.

Comparative regional dynamics and strategic imperatives highlighting how clinical priorities, regulation, and infrastructure influence device adoption across global markets

Regional dynamics exhibit distinct clinical priorities, regulatory environments, and procurement behaviors that influence adoption patterns and partnership strategies. In the Americas, healthcare delivery systems are characterized by a high degree of specialization, advanced imaging infrastructure, and a strong emphasis on minimally invasive diagnostic pathways. These factors favor devices that demonstrate procedural efficiency, reimbursement alignment, and interoperability with existing imaging platforms. Moreover, payer sensitivity and hospital budget cycles often dictate procurement timing and the uptake of higher-cost integrated solutions.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied capital intensity produce differentiated adoption timelines across subregions. Established markets in Western Europe prioritize conformity with stringent regulatory and safety standards, while emerging markets within the region focus on cost-effective solutions and scalable training models. Middle Eastern and African markets often present opportunities for partnership-based distribution models and localized servicing agreements, reflecting logistical complexities and diverse clinical infrastructure.

In the Asia-Pacific region, rapid investment in imaging capacity and a growing emphasis on early detection and minimally invasive care are catalyzing demand for devices that can be rapidly deployed and supported at scale. Several APAC markets are also notable for fast adoption of novel procedural workflows and for demand-driven customization to local clinical practices. Cross-border supply chain considerations and regional trade agreements further influence sourcing decisions, as manufacturers weigh proximity to growing centers of demand against manufacturing cost advantages. Overall, regional strategy must be adaptive, combining regulatory pathway planning with tailored commercial models that reflect local payer systems, clinical practice patterns, and infrastructure maturity.

Competitive landscape and partnership strategies that differentiate leaders through clinical evidence, integrated services, and scalable commercialization models

Competitive dynamics in the smart biopsy domain are shaped by a mix of established medical device firms, imaging system providers, nimble startups focused on niche procedural needs, and software-first companies that deliver navigation and analytics capabilities. These players differentiate through clinical evidence generation, system integration, after-sales service, and strategic partnerships. Firms that can demonstrate clear outcomes advantages-reduced complication rates, higher diagnostic yield, or improved workflow efficiency-tend to build stronger institutional relationships and justify premium contracting models.

In addition to product differentiation, route-to-market execution is a critical determinant of commercial success. Sales channel structures range from direct hospital partnerships and integrated imaging sales to distributor networks serving ambulatory and clinic environments. Service offerings that include training, maintenance, and consumable supply management are increasingly central to customer retention, and companies that align commercial incentives with clinical outcomes find it easier to negotiate value-based contracts.

Technology alliances are another key vector for competitive advantage. Collaborations with imaging manufacturers, cloud analytics providers, and clinical research networks accelerate time-to-evidence and broaden addressable use cases. Meanwhile, intellectual property around needle tip geometry, navigation algorithms, and software workflows creates defensive moats. The most resilient companies combine product excellence with scalable service models and a clear playbook for clinical validation across different procedure types and care settings.

Actionable multi-dimensional recommendations for manufacturers and healthcare leaders to secure supply resilience, clinical validation, and sustainable commercial differentiation

Industry leaders should adopt a multipronged strategy that balances near-term operational resilience with long-term platform differentiation. First, prioritize supply chain diversification and nearshoring where economically feasible to reduce exposure to trade policy volatility and to shorten lead times for critical components. This step should be accompanied by rigorous supplier qualification processes and scenario planning to maintain continuity for high-volume consumables such as needles and imaging accessories.

Second, invest in clinical evidence generation that aligns with the most commercially meaningful applications. Targeted prospective studies in breast, lung, liver, and prostate procedures that measure diagnostic yield, complication rates, and workflow efficiency will accelerate payer acceptance and hospital procurement decisions. Pair these studies with real-world evidence captured through integrated software to demonstrate longitudinal value.

Third, design modular platforms that enable cross-modal compatibility with CT, MRI, and ultrasound guidance. Such interoperability increases platform utilization across departments and improves return on capital for purchasers. Complement product modularity with flexible commercial models-leasing, outcome-based contracts, and bundled consumables-to address diverse purchasing preferences across hospitals, diagnostic centers, clinics, and ambulatory surgical centers.

Fourth, accelerate digital strategy by embedding guidance software, analytics, and remote support capabilities into product offerings. Digital features not only enhance procedural accuracy but also create recurring revenue pathways that are less sensitive to component tariffs. Finally, cultivate targeted channel partnerships and service infrastructures to ensure rapid deployment and high uptime in key regional markets, thereby strengthening customer loyalty and competitive differentiation.

A rigorous mixed-methods research framework that blends clinician interviews, supply chain analysis, regulatory review, and expert validation to ensure robust actionable insights

The research approach integrates qualitative and quantitative methods designed to triangulate market dynamics, clinical adoption drivers, and competitive positioning. Primary research included structured interviews with clinicians across specialties-radiology, interventional oncology, and urology-alongside procurement leaders at hospitals, ambulatory surgical centers, and diagnostic centers to capture firsthand perspectives on device requirements, workflow constraints, and purchasing criteria. These interviews were complemented by discussions with device engineers, regulatory specialists, and component suppliers to map development timelines and sourcing considerations.

Secondary research entailed systematic review of clinical literature, regulatory filings, and publicly available technical documentation to validate clinical claims and device feature sets. Where helpful, procedural guidelines and best-practice statements were synthesized to contextualize clinical utility. Data triangulation techniques were used to reconcile differing inputs, and sensitivity analysis framed how operational changes-such as tariff-driven cost pressures or shifts in reimbursement policy-could alter procurement calculus.

Throughout the process, findings were validated via expert panels comprising clinicians, health system administrators, and industry strategists to ensure pragmatic relevance. The methodology emphasizes transparency in assumptions, traceability of sources, and reproducibility of analytical steps so that stakeholders can apply insights directly to product planning, clinical trials design, and go-to-market execution.

A concise synthesis of clinical, technological, and strategic drivers that will determine which biopsy device strategies translate into sustained clinical adoption and commercial success

In summary, the evolution of smart biopsy devices reflects a broader shift toward integrated procedural solutions that combine precision guidance, optimized workflows, and software-enabled value capture. Clinical demand for minimally invasive, high-fidelity sampling is intersecting with technological progress in imaging and navigation, producing opportunities for differentiated platforms that can serve multiple applications and clinical environments. At the same time, external pressures-such as tariff changes and regional regulatory variation-are compelling manufacturers to reorient supply chains and commercial models to preserve margin and ensure uninterrupted clinical supply.

Moving forward, success will accrue to organizations that can demonstrate measurable clinical benefits, provide flexible commercial options tailored to diverse end users, and embed software-driven services that enhance procedural outcomes and create recurring revenue. The interplay between segmentation choices-product type, application, guidance technology, end-user, and component design-and regional strategy will determine which offerings scale effectively. For decision-makers, the imperative is to align R&D priorities with validated clinical needs, operational realities, and adaptable go-to-market tactics so that innovations translate into sustainable clinical adoption and long-term institutional partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Smart Biopsy Devices Market, by Product Type

  • 8.1. Automated
  • 8.2. Manual

9. Smart Biopsy Devices Market, by Guidance Technology

  • 9.1. CT Guided
  • 9.2. MRI Guided
  • 9.3. Ultrasound Guided

10. Smart Biopsy Devices Market, by Component

  • 10.1. Accessories
  • 10.2. Guidance Software
  • 10.3. Imaging Systems
  • 10.4. Needles
    • 10.4.1. Large Gauge
    • 10.4.2. Medium Gauge
    • 10.4.3. Small Gauge

11. Smart Biopsy Devices Market, by Application

  • 11.1. Breast
  • 11.2. Liver
  • 11.3. Lung
  • 11.4. Prostate

12. Smart Biopsy Devices Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals

13. Smart Biopsy Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Smart Biopsy Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Smart Biopsy Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Smart Biopsy Devices Market

17. China Smart Biopsy Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Angiotech Pharmaceuticals, Inc.
  • 18.6. Argon Medical Devices, Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. Boston Scientific Corporation
  • 18.10. Cardinal Health, Inc.
  • 18.11. CONMED Corporation
  • 18.12. Cook Group Incorporated
  • 18.13. Danaher Corporation
  • 18.14. DTR Medical Ltd. by Innovia Medical
  • 18.15. Fujifilm Holdings Corporation
  • 18.16. Gallini Srl
  • 18.17. Hologic, Inc.
  • 18.18. INRAD, Inc.
  • 18.19. Intact Medical Corporation
  • 18.20. Integra LifeSciences Corporation
  • 18.21. Leica Biosystems Nussloch GmbH
  • 18.22. Medtronic PLC
  • 18.23. Merit Medical Systems
  • 18.24. Olympus Corporation
  • 18.25. Precision Biopsy, LLC
  • 18.26. Scion Medical Technologies, LLC
  • 18.27. Stryker Corporation
  • 18.28. TransMed7, LLC
  • 18.29. TSK Laboratory Europe BV

LIST OF FIGURES

  • FIGURE 1. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SMART BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SMART BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CT GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MRI GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ULTRASOUND GUIDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LARGE GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY MEDIUM GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY SMALL GAUGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. GCC SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 137. GCC SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 138. GCC SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 158. G7 SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 159. G7 SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 165. NATO SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 166. NATO SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SMART BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA SMART BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY GUIDANCE TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY NEEDLES, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA SMART BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)